No current proven scientific evidence against using ibuprofen in treating symptoms of COVID-19
Reckitt Benckiser (RB), the makers of Nurofen, is aware of the ongoing spread of conflicting information concerning the use of steroids & non-steroidal anti-inflammatory products (NSAIDs), including ibuprofen, for the alleviation of COVID-19 symptoms.
Based on all available information, there is currently no proven scientific evidence linking over the counter use of ibuprofen to the aggravation of COVID-19.
The World Health Organization (WHO), European Medicines Agency (EMA), US Food and Drug Administration (FDA) and various other health authorities have also issued statements acknowledging an absence of conclusive scientific evidence on this topic.
- Full WHO statement available here.
- Full EMA statement available here.
- Full FDA statement available here.
Consumer safety is our number one priority. Ibuprofen is a well-established medicine with a good safety profile that has been used as a self-care fever and pain reducer, including in viral illnesses, for more than 30 years.
As with any medicine, we would remind consumers and their caregivers to carefully read and follow the instructions provided on the packaging and in the patient information leaflet. If you have any additional concerns speak to your healthcare provider.
As a responsible, science-led organisation, we are engaging with the relevant health authorities. We remain committed to communicating any additional information or guidance necessary for the safe use of our products should the need arise.